PMN · ProMIS Neurosciences Inc.
The latest filing no longer states the doubt (first flagged May 12, 2026).
View the 10-Q filed Aug 13, 2026Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Nov 28, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Nov 28, 2025.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMN
this stock
ProMIS Neurosciences Inc.
|
$128.96M | +119.3% | — | — | 3.2% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +21.5% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +16.5% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +5.0% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +18.1% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Nov 28, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMN | +0.1% | +3.4% | -24.6% | +9.2% | +119.3% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | +0.5% | +0.8% | -35.3% | +6.5% | +106.8% |